Nature Medicine
June 2023
Margaret Haney, Monique Vallée, Sandy Fabre et al.
Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and...
Biomedicine & Pharmacotherapy
March 24, 2022
Francisco Madrid-Gambin, Alex Gomez-Gomez, Arnau Busquets-García et al.
14 citations
There has been a renewed interest in the potential use of psychedelics for the treatment of psychiatric conditions. Nevertheless, little is known about the mechanism of action and molecular pathways influenced by ayahuasca use in humans. Therefore, for the first time, our study aims to investigate the human metabolomics signature after consumption of a psychedelic, ayahuasca, and its connection...
Nature
July 2020
Daniel Jimenez-Blasco, Arnau Busquets-García, Etienne Hebert-Chatelain et al.
Astrocytes take up glucose from the bloodstream to provide energy to the brain, thereby allowing neuronal activity and behavioural responses1-5. By contrast, astrocytes are under neuronal control through specific neurotransmitter receptors5-7. However, whether the activation of astroglial receptors can directly regulate cellular glucose metabolism to eventually modulate behavioural responses is...
Neuropsychopharmacology
June 2013
Emma Puighermanal, Arnau Busquets-García, Maria Gomis-Gonzalez et al.
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the...
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
December 5, 2012
Emma Puighermanal, Arnau Busquets-García, Rafaël Maldonado et al.
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of...